Vectalys set up its therapeutics unit, Flashcell and stayed focused on its manufacturing activity. Considering that safe & efficient delivery combined with manufacturing know-how is a therapeutic key of success, Vectalys has legitimately included therapeutic applications to its activities.
Vectalys sub-licensed in 2017 its new LentiFlash technology and rights to the clinical-stage biotechnology company, FlashCell, for a wide range of therapeutic applications including immunotherapy and gene editing approaches. In 2017, FlashCell carried out research programs to complete the intellectual portfolio and identify its own clinical programs.
A result of the merger of Vectalys & FlashCell: creation of a new leading integrated player within a new brand and a complete integrated offer, Flash Therapeutics will include both a manufacturing platform named Vectalys and a new therapeutic gene therapy unit.
First lentiviral vectors GMP batch from the Vectalys GMP Manufacturing Platform of Flash Therapeutics.